Harrow Health (HROW) Stock Forecast & Price Target

Compare

541 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HROW Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Harrow

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HROW Stock 12 Month Forecast

Average Price Target

$72.67

▲(63.71% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Harrow Health in the last 3 months. The average price target is $72.67 with a high forecast of $94.00 and a low forecast of $63.00. The average price target represents a 63.71% change from the last price of $44.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"23":"$23","41":"$41","59":"$59","77":"$77","95":"$95"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":94,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$94.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$72.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$63.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[23,41,59,77,95],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.78,43.95076923076923,48.121538461538464,52.29230769230769,56.463076923076926,60.63384615384615,64.80461538461537,68.97538461538461,73.14615384615385,77.31692307692308,81.4876923076923,85.65846153846154,89.82923076923076,{"y":94,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.78,42.31,44.84,47.370000000000005,49.900000000000006,52.43000000000001,54.96,57.49,60.02,62.550000000000004,65.08000000000001,67.61,70.14,{"y":72.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.78,41.566153846153846,43.35230769230769,45.13846153846154,46.924615384615386,48.71076923076923,50.496923076923075,52.28307692307692,54.06923076923077,55.855384615384615,57.64153846153846,59.42769230769231,61.21384615384615,{"y":63,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":41.86,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.72,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.23,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.72,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.37,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.77,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.78,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$94.00

Average Price Target$72.67

Lowest Price Target$63.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

11/18/25

Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW) and Butterfly Network (NYSE: BFLY)

Thomas Flaten

Lake Street

$70

Buy

57.69%

Upside

Reiterated

11/18/25

Harrow Health (HROW) Receives a Buy from Lake Street

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

11/18/25

Strategic Acquisition and Innovative Pipeline Drive Buy Rating for Harrow HealthWe believe Harrow is advancing its position as a leader in the U.S. ophthalmic pharmaceutical market with the growth of its FDA- approved franchise. We expect near-term interest to focus on the ongoing launch of Vevye and its volume growth and net price outlook, continued growth of Iheezo, and the ongoing launch of Triesence in both the retina market and surgical market. We expect the seasonality in the company’s underlying business could drive some volatility in the stock, but we believe the long-term growth outlook for the company is attractive and rate shares Outperform.

Jeffrey Cohen

Ladenburg Thalmann & Co.

$64→$66

Buy

48.68%

Upside

Reiterated

11/12/25

Harrow price target raised to $66 from $64 at LadenburgHarrow price target raised to $66 from $64 at Ladenburg

Yi Chen

H.C. Wainwright

$64→$69

Buy

55.44%

Upside

Reiterated

11/12/25

Harrow Health's Strong Financial Performance and Strategic Initiatives Justify Buy Rating with Revised Price Target

Steven Seedhouse

Cantor Fitzgerald

$76→$94

Buy

111.76%

Upside

Reiterated

11/11/25

Harrow price target raised to $94 from $76 at Cantor FitzgeraldHarrow price target raised to $94 from $76 at Cantor Fitzgerald

Thomas Shrader

BTIG

$63

Buy

41.92%

Upside

Reiterated

11/11/25

Harrow Health: Strong Growth Prospects and Strategic Market Expansion Drive Buy Rating

Mayank Mamtani

B. Riley Securities

$70→$74

Buy

66.70%

Upside

Reiterated

10/01/25

Harrow price target raised to $74 from $70 at B. RileyHarrow price target raised to $74 from $70 at B. Riley

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Chase Knickerbocker

Craig-Hallum

―

Buy

―

Reiterated

11/18/25

Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW) and Butterfly Network (NYSE: BFLY)

Thomas Flaten

Lake Street

$70

Buy

57.69%

Upside

Reiterated

11/18/25

Harrow Health (HROW) Receives a Buy from Lake Street

Lachlan Hanbury Brown

William Blair

―

Buy

―

Reiterated

11/18/25

Jeffrey Cohen

Ladenburg Thalmann & Co.

$64→$66

Buy

48.68%

Upside

Reiterated

11/12/25

Harrow price target raised to $66 from $64 at LadenburgHarrow price target raised to $66 from $64 at Ladenburg

Yi Chen

H.C. Wainwright

$64→$69

Buy

55.44%

Upside

Reiterated

11/12/25

Harrow Health's Strong Financial Performance and Strategic Initiatives Justify Buy Rating with Revised Price Target

Steven Seedhouse

Cantor Fitzgerald

$76→$94

Buy

111.76%

Upside

Reiterated

11/11/25

Harrow price target raised to $94 from $76 at Cantor FitzgeraldHarrow price target raised to $94 from $76 at Cantor Fitzgerald

Thomas Shrader

BTIG

$63

Buy

41.92%

Upside

Reiterated

11/11/25

Harrow Health: Strong Growth Prospects and Strategic Market Expansion Drive Buy Rating

Mayank Mamtani

B. Riley Securities

$70→$74

Buy

66.70%

Upside

Reiterated

10/01/25

Harrow price target raised to $74 from $70 at B. RileyHarrow price target raised to $74 from $70 at B. Riley

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Harrow Health

1 Month

xxx

Success Rate

13/18 ratings generated profit

Average Return

+7.66%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.22% of your transactions generating a profit, with an average return of +7.66% per trade.

3 Months

xxx

Success Rate

13/18 ratings generated profit

Average Return

+32.93%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.22% of your transactions generating a profit, with an average return of +32.93% per trade.

1 Year

Chase KnickerbockerCraig-Hallum

Success Rate

15/18 ratings generated profit

Average Return

+36.65%

reiterated a buy rating last month

Copying Chase Knickerbocker's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +36.65% per trade.

2 Years

xxx

Success Rate

17/18 ratings generated profit

Average Return

+61.89%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 94.44% of your transactions generating a profit, with an average return of +61.89% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HROW Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HROW has received 16 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. HROW average Analyst price target in the past 3 months is 72.67.

Each month's total comprises the sum of three months' worth of ratings.

HROW Financial Forecast

HROW Earnings Forecast

Next quarter’s earnings estimate for HROW is $0.39 with a range of $0.14 to $0.64. The previous quarter’s EPS was $0.03. HROW beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year HROW has Performed in-line its overall industry.

HROW Sales Forecast

Next quarter’s sales forecast for HROW is $91.59M with a range of $88.70M to $97.83M. The previous quarter’s sales results were $71.64M. HROW beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year HROW has Performed in-line its overall industry.

HROW Stock Forecast FAQ

What is HROW’s average 12-month price target, according to analysts?

Based on analyst ratings, Harrow Health Inc’s 12-month average price target is 72.67.

What is HROW’s upside potential, based on the analysts’ average price target?

Harrow Health Inc has 63.71% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HROW a Buy, Sell or Hold?

Harrow Health Inc has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Harrow Health Inc’s price target?

The average price target for Harrow Health Inc is 72.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $94.00 ,the lowest forecast is $63.00. The average price target represents 63.71% Increase from the current price of $44.39.

What do analysts say about Harrow Health Inc?

Harrow Health Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of HROW?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Harrow Health (HROW) Stock Forecast & Price Target

HROW Analyst Ratings

HROW Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Harrow Health

HROW Analyst Recommendation Trends

HROW Financial Forecast

HROW Earnings Forecast

HROW Sales Forecast

HROW Stock Forecast FAQ

Detailed List of Analyst Forecasts